))
Setting Up a Robust CGT Supply Chain (Part 1)
Manage episode 409189939 series 3554424
内容由Quick Group of Companies提供。所有播客内容（包括剧集、图形和播客描述）均由 Quick Group of Companies 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Cell & Gene Therapies hold incredible potential for improving – if not saving – human lives. These CGT’s have been called “living drugs” and can heal diseased organs and – we hope – fight diseases that currently have no cure.
Because of these incredible possibilities, related research and development is growing exponentially around the globe, with increasing numbers of complex clinical trials – complex because they require precisely-timed pickup and delivery of specimens and therapies. A single hiccup anywhere in terms of pickup, drop-off, temperature – anything – can cause significant challenges.
So what, exactly, does it take to set up a robust Cell & Gene Therapy supply chain? What should manufacturers, labs, pharmaceutical & biotech companies, and logistics providers consider?
Mike Sweeney can explain. Mike is Global Head of Strategy for CGT and Direct to Patient products (CGT and DTP) at QuickSTAT Global Life Science Logistics. He joins me now to discuss why – for CGT Supply Chains – planning in advance is the best medicine.
4集单集
分享
